Evidence map›Paper›PMID 39652347›Full record

Observational studyJAMA network open2024

West African Genetic Ancestry and Breast Cancer Outcomes Among Black Women.

Sonya Reid, Run Fan, Lindsay Venton, Anne Weidner, Ann Tezak, Mya L Roberson, Susan Vadaparampil, Xuefeng Wang, Sean Yoder, Marilin Rosa and 7 more

Abstract readObservational Study
In one paragraph

Observational study in JAMA network open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Sonya ReidDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Run FanDepartment of Biostatistics and Bioinformatics, Vanderbilt University Medical Center, Nashville, Tennessee.
Lindsay VentonDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Anne WeidnerDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Ann TezakDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Mya L RobersonDepartment of Health Policy and Management, University of North Carolina at Chapel Hill, Chapel Hill.
Susan VadaparampilMoffitt Cancer Center, Tampa, Florida.
Xuefeng WangMoffitt Cancer Center, Tampa, Florida.
Sean YoderMoffitt Cancer Center, Tampa, Florida.
Marilin RosaMoffitt Cancer Center, Tampa, Florida.
Jibril HirboDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Jennifer G WhisenantDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Jennifer PietenpolDepartment of Biochemistry, Vanderbilt University Medical Center, Nashville, Tennessee.
Padma Sheila RajagopalCenter for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Brian LehmannDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Fei YeDepartment of Biostatistics and Bioinformatics, Vanderbilt University Medical Center, Nashville, Tennessee.
Tuya PalDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STACIE B DUSETZINA · 1995 to 2026
$172.8M
TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI Christine O'Connell · 1998 to 2026
$93.5M
TISSUE CoreP50CA098131 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PARK, BEN HO, PIETENPOL, JENNIFER A · 2003 to 2024
$48.7M
From pathogenesis to new therapeutic targets in Diffuse Large B cell LymphomaR35CA210105 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Riccardo Dalla-Favera · 2016 to 2026
$10.0M
Breast Cancer In Blacks: Impact of Genomics, Healthcare Use and Lifestyle on Outcomes (BRIGHT)R01CA204819 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PAL, TUYA · 2017 to 2021
$1.8M
NCI NIH HHS P30 CA068485NCI NIH HHS P30 CA076292NCI NIH HHS P50 CA098131NCI NIH HHS R01 CA204819NCI NIH HHS R35 CA210105
6 · The paper itself

Abstract

Importance: Young Black women bear a disproportionate burden of breast cancer deaths compared with White women, yet they remain underrepresented in genomic studies. Objective: To evaluate the association of biological factors, including West African genetic ancestry, and nonbiological factors with disease-free survival (DFS) among young Black women with breast cancer. Design, Setting, and Participants: This observational cohort study included Black women diagnosed with invasive breast cancer between January 1, 2005, and December 31, 2016. Participants diagnosed with breast cancer at age 50 years or younger were recruited through the Florida and Tennessee state cancer registries. The final analysis was completed between June and September 2024. Exposure: West African genetic ancestry. Main Outcomes and Measures: A multivariable model was developed to evaluate the association between West African genetic ancestry and breast cancer DFS, adjusting for immunohistochemistry subtype, lymph node (LN) status, and full-time employment. Results: This study included 687 Black women with early-stage invasive breast cancer. Their median age at diagnosis was 44 years (IQR, 38-47 years), and the median follow-up was 10 years (IQR, 7-11 years). In multivariable analysis, triple-negative breast cancer (TNBC) and LN involvement were associated with shorter breast cancer DFS (hazard ratio, 1.81 [95% CI, 1.20-2.73] and 1.77 [95% CI, 1.30-2.41], respectively), whereas full-time employment was associated with improved outcomes (hazard ratio, 0.44 [95% CI, 0.30-0.63]). Among the 551 participants for whom global genetic ancestry could be assessed, having a higher percentage of West African genetic ancestry was associated with shorter breast cancer DFS among 246 participants in the hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (ERBB2 [formerly HER2])-negative subgroup (hazard ratio, 1.45 [95% CI, 1.04-2.04]). Of the 369 participants (53.7%) with PAM50 data available, basal (133 [36.0%]) and luminal B (107 [29.0%]) subtypes were the most common. Among the 179 patients with HR-positive/ERBB2-negative disease and PAM50 data available, luminal B and basal subtypes combined were also overrepresented (81 [45.3%] and 24 [13.4%], respectively) compared with luminal A (70 [39.1%]). Conclusions and Relevance: In this study of young Black women with breast cancer, having a higher percentage of West African genetic ancestry, TNBC, and LN involvement were associated with shorter breast cancer DFS. Interestingly, full-time employment was associated with improved breast cancer DFS. These findings highlight the importance of considering genetic ancestry beyond self-reported race and accounting for social determinants of health, in efforts to improve survival outcomes among Black women with breast cancer.

Indexed as

Black or African AmericanBreast NeoplasmsAdultAfrica, WesternCohort StudiesDisease-Free SurvivalFemaleFloridaHumansMiddle AgedTennessee

Identifiers

PMID39652347
PMCPMC11629124

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.